May 13, 2024 — Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional dyspnoea and decreased exercise capacity. A major cause of this in HCM patients is left ventricular outflow tract (LVOT) obstruction, which results in elevated intracardiac pressures.

May 10, 2024 — Scientists from Immanuel Kant Baltic Federal University proved that Raman spectroscopy, a method by which diffusion property of substances is analyzed, can be used in diagnosing of coronary vascular diseases. In particular, this method turned out to be available for identification of acute coronary syndrome, the abrupt decrease of blood flow due to arteriostenosis.

May 10, 2024 — According to the Summa Cum Laude Award-Winning Online Poster presented during the 

35th Annual Cardiovascular Interventions

May 9, 2024 — The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM).

May 8, 2024 —  The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our continued safety and quality concerns with the following Getinge/Maquet cardiovascular medical devices:

May 8, 2024 — 4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for the AltaValve System, a transcatheter mitral valve replacement (TMVR) device.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now